Tubeimoside I | CAS#102040-03-9 | anti-tumor agent

MedKoo Cat#: 562261 | Name: Tubeimoside I

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tubeimoside I is an anti-tumor agent. It acts by inducing cell cycle arrest and apoptosis, activating caspase, p53 Fas, TNFa, NF-kB and JNK pathways, and regulating Bcl-2, Bak and Bax.

Chemical Structure

Tubeimoside I

CAS#102040-03-9

Theoretical Analysis

MedKoo Cat#: 562261

Name: Tubeimoside I

CAS#: 102040-03-9

Chemical Formula: C63H98O29

Exact Mass: 1318.6194

Molecular Weight: 1319.44

Elemental Analysis: C, 57.35; H, 7.49; O, 35.16

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 220.00
25mg	USD 410.00
50mg	USD 680.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Tubeimoside I; Tubeimoside-I; Tubeimoside A; Lobatoside H;

IUPAC/Chemical Name

(2β,3β,4α)-olean-12-en-28-oic acid, 3-[[2-O-[4-O-[(3S)-4-carboxy-3-hydroxy-3-methyl-1-oxobutyl]-α-L-arabinopyranosyl]-β-D-glucopyranosyl]oxy]-2,23-dihydroxy-28-(O-β-D-xylopyranosyl-(1→3)-O-6-deoxy-α-L-mannopyranosyl-(1→2)-α-L-arabinopyranosyl) ester, intramol. 4''(3)→4''(28)-ester

InChi Key

UNEIHPFYJFFHGD-UMVHPKKKSA-N

InChi Code

InChI=1S/C63H98O29/c1-26-45-46(88-51-43(77)38(72)30(67)22-81-51)44(78)52(84-26)89-48-40(74)32(69)24-83-54(48)92-56(79)63-15-13-57(2,3)17-28(63)27-9-10-35-59(5)18-29(66)50(60(6,25-65)34(59)11-12-62(35,8)61(27,7)14-16-63)91-55-49(42(76)41(75)33(21-64)85-55)90-53-47(39(73)31(68)23-82-53)87-37(71)20-58(4,80)19-36(70)86-45/h9,26,28-35,38-55,64-69,72-78,80H,10-25H2,1-8H3/t26-,28-,29-,30-,31-,32-,33+,34+,35+,38+,39-,40-,41+,42-,43-,44+,45-,46-,47+,48+,49+,50-,51+,52-,53-,54-,55-,58+,59-,60-,61+,62+,63-/m0/s1

SMILES Code

O[C@H]1[C@H](O)[C@@H](O[C@H](OC[C@H](O)[C@@H]2O)[C@@H]2OC3=O)[C@H](O[C@@H]4[C@@](C)(CO)[C@H](CC[C@]5(C)[C@@H]6CC=C7[C@]5(CC[C@]8(C(O[C@@H]9OC[C@H](O)[C@H](O)[C@H]9O[C@@H]%10O[C@@H](C)[C@H](OC(C[C@@](O)(C3)C)=O)[C@@H](O[C@H]%11OC[C@H](O)[C@@H](O)[C@@H]%11O)[C@H]%10O)=O)[C@H]7CC(C)(C)CC8)C)[C@]6(C)C[C@@H]4O)O[C@@H]1CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,319.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yang X, Li X, Luo M, Guo Y, Li C, Lv D, Cheng Z, Huang L, Shang FF, Huang B, Shen J, Luo S, Yan J. Corrigendum to "Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway" [J. Ethonopharmacol. 267 (2021) 113642]. J Ethnopharmacol. 2024 Dec 24:119267. doi: 10.1016/j.jep.2024.119267. Epub ahead of print. Erratum for: J Ethnopharmacol. 2021 Mar 1;267:113642. doi: 10.1016/j.jep.2020.113642. PMID: 39721928. 2: Wen J, Li Y, Qin Y, Yan L, Zhang K, Li A, Wang Z, Yu F, Lai J, Yang W, Liu YU, Qin D, Su H. Lycorine protects motor neurons against TDP-43 proteinopathy- induced degeneration in cross-species models with amyotrophic lateral sclerosis. Pharmacol Res. 2024 Dec;210:107518. doi: 10.1016/j.phrs.2024.107518. Epub 2024 Nov 26. PMID: 39603574. 3: Li S, Liu Y, Sui X, Zhuo Y, Siqi H, Sijia Z, Hui Z, Dihua L, Dapeng Z, Lei Y. Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer. Nanomedicine (Lond). 2024;19(24):1977-1993. doi: 10.1080/17435889.2024.2382076. Epub 2024 Sep 3. PMID: 39225145; PMCID: PMC11485868. 4: Wu T, Yu Y, Tu X, Ye L, Wang J, Xie C, Kuang K, Yu Y, Zhuge W, Wang Z, Cui R, Zheng Y. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025 Jan 10;336:118754. doi: 10.1016/j.jep.2024.118754. Epub 2024 Aug 28. PMID: 39208999. 5: Thien ND, Hai-Nam N, Anh DT, Baecker D. Piezo1 and its inhibitors: Overview and perspectives. Eur J Med Chem. 2024 Jul 5;273:116502. doi: 10.1016/j.ejmech.2024.116502. Epub 2024 May 14. PMID: 38761789. 6: Liu Q, Zhong Z, Zheng S, Chu Y, Sakamoto N, Kuno T, Fang Y. Identification and characterization of a novel antifungal compound tubeimoside I targeting cell wall. Microbiol Spectr. 2024 Jun 4;12(6):e0404723. doi: 10.1128/spectrum.04047-23. Epub 2024 Apr 23. PMID: 38651884; PMCID: PMC11237440. 7: Wang R, Zheng K, Liu Y, Ji S, Tang Y, Wang J, Jiang R. Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes. Xenobiotica. 2024 Feb;54(2):57-63. doi: 10.1080/00498254.2023.2301352. Epub 2024 Jan 12. PMID: 38166553. 8: Hu D, Cui L, Zhang S, He S, Zhuo Y, Li D, Zhang L, Wang Y, Yang L, Wang X. Antitumor effect of tubeimoside-I on murine colorectal cancers through PKM2-dependent pyroptosis and immunomodulation. Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):4069-4087. doi: 10.1007/s00210-023-02855-1. Epub 2023 Nov 27. PMID: 38010398. 9: Song SR, Seo SU, Woo SM, Yoon JY, Yook S, Kwon TK. Tubeimoside-1 Enhances TRAIL-Induced Apoptotic Cell Death through STAMBPL1-Mediated c-FLIP Downregulation. Int J Mol Sci. 2023 Jul 24;24(14):11840. doi: 10.3390/ijms241411840. PMID: 37511599; PMCID: PMC10380985. 10: Han Z, Jin J, Chen X, He Y, Sun H. Adjuvant activity of tubeimosides by mediating the local immune microenvironment. Front Immunol. 2023 Feb 10;14:1108244. doi: 10.3389/fimmu.2023.1108244. PMID: 36845089; PMCID: PMC9950507. 11: Zhang W, Fan Z, Wang F, Yin L, Wu J, Li D, Song S, Wang X, Tang Y, Huang C. Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3. Oxid Med Cell Longev. 2023 Jan 14;2023:9966355. doi: 10.1155/2023/9966355. PMID: 36691640; PMCID: PMC9867588. 12: Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, Xu L, Zeng Z, Xu W, Yin Z, Ma W, Wang Q. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022 May;99:154016. doi: 10.1016/j.phymed.2022.154016. Epub 2022 Feb 27. PMID: 35278900. 13: Lv D, Luo M, Cheng Z, Wang R, Yang X, Guo Y, Huang L, Li X, Huang B, Shen J, Luo S, Yan J. Tubeimoside I Ameliorates Myocardial Ischemia-Reperfusion Injury through SIRT3-Dependent Regulation of Oxidative Stress and Apoptosis. Oxid Med Cell Longev. 2021 Nov 9;2021:5577019. doi: 10.1155/2021/5577019. PMID: 34795840; PMCID: PMC8595016. 14: Cheng Z, Lv D, Luo M, Wang R, Guo Y, Yang X, Huang L, Li X, Li C, Shang FF, Huang B, Shen J, Luo S, Yan J. Tubeimoside I protects against sepsis-induced cardiac dysfunction via SIRT3. Eur J Pharmacol. 2021 Aug 15;905:174186. doi: 10.1016/j.ejphar.2021.174186. Epub 2021 May 24. PMID: 34033817. 15: Ju X, Zhu Y, Wang Y, Li J, Zhang J, Gong M, Ren W, Li S, Zhong J, Zhang L, Zhang QC, Zhang R, Ding Q. A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathog. 2021 Mar 12;17(3):e1009439. doi: 10.1371/journal.ppat.1009439. PMID: 33711082; PMCID: PMC7990224. 16: Yang X, Li X, Luo M, Li C, Huang L, Li X, Huang B, Shen J, Luo S, Yan J. Tubeimoside I improves endothelial function in sepsis via activation of SIRT3. Lab Invest. 2021 Jul;101(7):897-907. doi: 10.1038/s41374-021-00580-y. Epub 2021 Mar 4. PMID: 33664465. 17: Du J, Dong Z, Tan L, Tan M, Zhang F, Zhang K, Pan G, Li C, Shi S, Zhang Y, Liu Y, Cui H. Tubeimoside I Inhibits Cell Proliferation and Induces a Partly Disrupted and Cytoprotective Autophagy Through Rapidly Hyperactivation of MEK1/2-ERK1/2 Cascade via Promoting PTP1B in Melanoma. Front Cell Dev Biol. 2020 Dec 17;8:607757. doi: 10.3389/fcell.2020.607757. PMID: 33392197; PMCID: PMC7773826. 18: Yang X, Li X, Luo M, Guo Y, Li C, Lv D, Cheng Z, Huang L, Shang FF, Huang B, Shen J, Luo S, Yan J. Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. J Ethnopharmacol. 2021 Mar 1;267:113642. doi: 10.1016/j.jep.2020.113642. Epub 2020 Nov 29. Erratum in: J Ethnopharmacol. 2024 Dec 24:119267. doi: 10.1016/j.jep.2024.119267. PMID: 33264658. 19: Wang K, Zhan Y, Chen B, Lu Y, Yin T, Zhou S, Zhang W, Liu X, Du B, Wei X, Xiao J. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020 Aug 26;11(8):708. doi: 10.1038/s41419-020-02915-x. PMID: 32848130; PMCID: PMC7449972. 20: Cao LJ, Xie HT, Chu ZX, Ma Y, Wang MM, Shi Z. Tubeimoside‑1 induces apoptosis in human glioma U251 cells by suppressing PI3K/Akt‑mediated signaling pathways. Mol Med Rep. 2020 Aug;22(2):1527-1535. doi: 10.3892/mmr.2020.11224. Epub 2020 Jun 11. PMID: 32627020; PMCID: PMC7339596.